Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044836 | 0.94 | MAPT (0.69) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL315785 | 0.88 | MGLL (0.69) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL1183642 | 0.87 | MGLL (0.68) | ALDH1A1MAPTLMNASMN1; SMN2MGLL | |
| SCHEMBL27851988 | 0.84 | MAPT (0.61) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL12240580 | 0.82 | SIRT6 (0.74) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL9279984 | 0.82 | KMT2A (0.73) | ALDH1A1MAPTLMNASMN1; SMN2MGLL | |
| SCHEMBL3893386 | 0.81 | MAPT (0.62) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL1734128 | 0.81 | MGLL (0.63) | ALDH1A1MGLLCYP1A2CYP2D6 | |
| SCHEMBL2105411 | 0.81 | MAPT (0.75) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL3996605 | 0.81 | MGLL (0.63) | ALDH1A1MGLLCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2229362-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | AstraZeneca AB (SE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181967-A1 | New compounds I | GPR119, GLP1R, FABP4 | ALDH1A1 2089/4885MAPT 4536/4885LMNA 1076/4885 |
| US-20110046135-A1 | NEW COMPOUNDS I | GPR119, GLP1R, FABP4 | ALDH1A1 2089/4885MAPT 4536/4885LMNA 1076/4885 |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | GPR119, FABP4, ADIPOR2 | ALDH1A1 1389/4885MAPT 4640/4885LMNA 1785/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | ALDH1A1 2717/4885MAPT 4470/4885LMNA 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.